Insulin-Like Growth Factor Binding Protein 2
"Insulin-Like Growth Factor Binding Protein 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.
| Descriptor ID |
D018971
|
| MeSH Number(s) |
D12.776.157.420.260
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Insulin-Like Growth Factor Binding Protein 2".
Below are MeSH descriptors whose meaning is more specific than "Insulin-Like Growth Factor Binding Protein 2".
This graph shows the total number of publications written about "Insulin-Like Growth Factor Binding Protein 2" by people in this website by year, and whether "Insulin-Like Growth Factor Binding Protein 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 0 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 4 | 1 | 5 |
| 2014 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin-Like Growth Factor Binding Protein 2" by people in Profiles.
-
Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. J Cachexia Sarcopenia Muscle. 2021 06; 12(3):704-716.
-
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.
-
IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett. 2021 03 01; 500:132-146.
-
IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene. 2020 03; 39(11):2243-2257.
-
Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. Int J Cardiol. 2020 02 01; 300:245-251.
-
Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS One. 2017; 12(7):e0181204.
-
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients. 2017 Apr 12; 9(4).
-
IGFBP2 Activates the NF-?B Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2016 11 15; 76(22):6543-6554.
-
Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016 09; 68(9):1303-9.
-
Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies. J Pathol. 2016 07; 239(3):355-64.